TIDMSCLP

RNS Number : 3786M

Scancell Holdings Plc

14 September 2023

14 September 2023

Scancell Holdings plc

("Scancell" or the "Company")

Scancell to present three posters at the Seventh International Cancer Immunotherapy Conference

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces it will present three posters at the Seventh International Cancer Immunotherapy Conference, jointly organised by the American Association for Cancer Research, the European Network for Cancer Immunotherapy and the Cancer Research Institute and taking place on 20-23 September 2023 in Milan, Italy.

Prof Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of Scancell, commented: "We look forward to presenting at such a prestigious meeting and sharing data on our preclinical programmes with the scientific community. As previously disclosed in a recent business update , we continue to make great progress in the clinic with our two lead cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1 currently in Phase 1/2 clinical trials as well as leveraging the value of our antibody platform to generate revenue through high value licence agreements.

"Showcasing the potential of our technology platforms to generate further pipeline assets with high value partnering opportunities, we will be presenting encouraging data on both the Moditope(R) and GlyMab(R) platforms. Data on antibody candidates derived from the GlyMab(R) platform illustrate the potential of these assets as chimeric antigen receptor T cell (CAR-T) therapies and could lead to out licensing opportunities with cell therapy companies. Furthermore, we will be presenting data bolstering the potential of Modi-2 as a solid tumour cancer therapy and further characterising the response to Moditope(R) peptides in preclinical studies."

The title, timing and location of the poster presentation are as follows:

Poster 1

 
 Poster presentation   Anti-sialyl-di-lewisa CAR T cells for effective 
  title                 anti-tumour therapy 
 Authors               Iniobong Charles, Katherine Cook, Bubacarr 
                        Kaira, Gaëlle Cane, Anne Skinner, Alissa 
                        Wright, Mireille Vankemmelbeke, Rachael Metheringham, 
                        Victoria Brentville and Lindy Durrant 
 Session title         Poster Session A 
 Session date and      12.30 - 14.00 CET, 21(st) September, 2023 
  time 
 Location              Poster Board number P232

Poster 2

 
 Poster presentation   Vaccination stimulating post-translational 
  title                 modification specific Th1 responses repolarises 
                        the tumour environment to reduce suppressive 
                        LAP expressing T cells 
 Authors               Suha Atabani, Katherine Cook, Peter Symonds, 
                        Ian Daniels, Ruhul Choudhury, Alissa Wright, 
                        Anne Skinner, Victoria Brentville and Lindy 
                        Durrant 
 Session title         Poster Session A 
 Session date and      12.30 - 14.00 CET, 21(st) September, 2023 
  time 
 Location              Poster Board number P230

Poster 3

 
 Poster presentation   Modi-2, a vaccine targeting homocitrullinated 
  title                 self-epitopes, stimulates potent CD4-mediated 
                        anti-tumour responses as a therapy for solid 
                        cancers 
 Authors               Abdullah Al-Omari, Katherine Cook, Peter Symonds, 
                        Anne Skinner, Yaling Zhu, Vince Coble, Nazim 
                        Uddin, Priscilla Ranglani, Adrian Parry, Sally 
                        Adams, Geoffrey Lynn, Lindy Durrant and Victoria 
                        Brentville 
 Session title         Poster Session B 
 Session date and      12.45 - 14.00 CET, 22(nd) September, 2023 
  time 
 Location              Poster Board number P217

Copies of the poster will be available on Scancell's website following the conference at: https://www.scancell.co.uk/vaccine-publications

 
 For further information, please contact: 
 
 Scancell Holdings plc                                                                   +44 (0) 20 3727 1000 
 Dr Jean-Michel Cosséry, Non-Executive Chairman 
 Professor Lindy Durrant, CEO 
 
 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)                     +44 (0) 20 7710 7600 
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking) 
 Nick Adams/Nick Harland (Corporate Broking) 
 
 Panmure Gordon (UK) Limited (Joint Broker)                                              +44 (0) 20 7886 2500 
 Freddy Crossley/Emma Earl (Corporate Finance) 
 Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications                                                      Tel.: +44 (0) 20 3709 5700 
 Mary-Jane Elliott/Matthew Neal/Chris Welsh                                              scancell@consilium-comms.com

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope (R) and ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody (R) ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab(R) ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab (R) ).

For further information about Scancell, please visit: https://www.scancell.co.uk/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSFIFUDEDSEIU

(END) Dow Jones Newswires

September 14, 2023 02:00 ET (06:00 GMT)

Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Scancell
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Scancell